Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
0.423
+0.041 (10.54%)
Nov 8, 2024, 2:26 PM EST - Market open
Citius Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Jun '24 Jun 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | Sep '19 Sep 30, 2019 |
Selling, General & Admin | 29.2 | 21.91 | 15.66 | 11.29 | 8.9 | 7 | |
Research & Development | 11.87 | 14.82 | 17.66 | 12.24 | 8.81 | 8.6 | |
Operating Expenses | 41.07 | 36.73 | 33.32 | 23.53 | 17.71 | 15.6 | |
Operating Income | -41.07 | -36.73 | -33.32 | -23.53 | -17.71 | -15.6 | |
Interest Expense | - | - | - | -0.01 | -0.02 | -0.02 | |
Interest & Investment Income | 0.97 | 1.18 | 0.25 | 0.26 | 0.07 | 0.05 | |
Other Non Operating Income (Expenses) | - | - | - | - | 0.11 | - | |
EBT Excluding Unusual Items | -40.1 | -35.55 | -33.06 | -23.28 | -17.55 | -15.56 | |
Gain (Loss) on Sale of Assets | 2.39 | 3.59 | - | - | - | - | |
Other Unusual Items | - | - | - | 0.23 | - | - | |
Pretax Income | -37.72 | -31.97 | -33.06 | -23.05 | -17.55 | -15.56 | |
Income Tax Expense | 0.58 | 0.58 | 0.58 | - | - | - | |
Net Income | -38.29 | -32.54 | -33.64 | -23.05 | -17.55 | -15.56 | |
Preferred Dividends & Other Adjustments | 1.47 | 1.15 | - | 1.45 | - | - | |
Net Income to Common | -39.77 | -33.69 | -33.64 | -24.51 | -17.55 | -15.56 | |
Shares Outstanding (Basic) | 163 | 151 | 146 | 109 | 39 | 20 | |
Shares Outstanding (Diluted) | 163 | 151 | 146 | 109 | 39 | 20 | |
Shares Change (YoY) | 9.86% | 3.57% | 34.52% | 177.28% | 94.25% | 87.87% | |
EPS (Basic) | -0.24 | -0.22 | -0.23 | -0.23 | -0.45 | -0.77 | |
EPS (Diluted) | -0.24 | -0.22 | -0.23 | -0.23 | -0.45 | -0.77 | |
Free Cash Flow | -29.09 | -29.06 | -28.36 | -24.26 | -16.93 | -12.44 | |
Free Cash Flow Per Share | -0.18 | -0.19 | -0.19 | -0.22 | -0.43 | -0.62 | |
EBITDA | -41.07 | -36.73 | -33.31 | -23.53 | -17.71 | -15.6 | |
D&A For EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | |
EBIT | -41.07 | -36.73 | -33.32 | -23.53 | -17.71 | -15.6 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.